Ticker >

Sandu Pharmaceutical share price

Sandu Pharmaceuticals Ltd.

BSE: 524703 SECTOR: Pharmaceuticals & Drugs  8918   21   0

55.01
-2.72 (-4.71%)
BSE: 25 Oct 03:21 PM

Price Summary

Today's High

₹ 57.36

Today's Low

₹ 54.56

52 Week High

₹ 85

52 Week Low

₹ 54

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

53.15 Cr.

Enterprise Value

50.86 Cr.

No. of Shares

0.97 Cr.

P/E

35.03

P/B

1.66

Face Value

₹ 10

Div. Yield

1.36 %

Book Value (TTM)

₹  33.04

CASH

2.29 Cr.

DEBT

0 Cr.

Promoter Holding

42.9 %

EPS (TTM)

₹  1.57

Sales Growth

-0.23%

ROE

5.3 %

ROCE

7.94%

Profit Growth

-4.12 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.23%
3 Year10.49%
5 Year5.92%

Profit Growth

1 Year-4.12%
3 Year28.37%
5 Year22.1%

ROE%

1 Year5.3%
3 Year5.54%
5 Year4.76%

ROCE %

1 Year7.94%
3 Year8.39%
5 Year7.71%

Debt/Equity

0

Price to Cash Flow

240.26

Interest Cover Ratio

28.8907035175879

CFO/PAT (5 Yr. Avg.)

3.34282110498673

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 42.90 0.00
Jun 2024 42.90 0.00
Mar 2024 42.90 0.00
Dec 2023 42.90 0.00
Sep 2023 42.90 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 28.8907035175879.
  • The company has an efficient Cash Conversion Cycle of 6.9882065197633 days.
  • The company has a good cash flow management; CFO/PAT stands at 3.34282110498673.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 9.06191355881287.

 Limitations

  • The company has shown a poor revenue growth of 10.491645329937% for the Past 3 years.
  • Company has a poor ROE of 5.54116434828535% over the past 3 years.
  • The company has a low EBITDA margin of 3.7431495888961% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 17.66 16.61 17.43 15.6 17.05
Total Expenditure 17.3 15.78 16.92 14.99 16.64
Operating Profit 0.35 0.83 0.51 0.6 0.41
Other Income 0 0.09 0.03 0.31 0.05
Interest 0.02 0.02 0.02 0.01 0.02
Depreciation 0.12 0.13 0.14 0.19 0.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.21 0.77 0.38 0.72 0.27
Tax 0.1 0.21 0.17 0.12 0.1
Profit After Tax 0.11 0.55 0.21 0.59 0.17
Adjusted EPS (Rs) 0.11 0.57 0.21 0.61 0.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 49.42 48.45 58.76 65.5 65.35
Total Expenditure 47.33 46.91 56.6 62.63 62.86
Operating Profit 2.09 1.53 2.16 2.87 2.49
Other Income 0.57 0.38 0.19 0.08 0.33
Interest 1.01 0.43 0.12 0.11 0.08
Depreciation 0.64 0.55 0.56 0.53 0.52
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.02 0.92 1.68 2.32 2.22
Tax 0.35 0.2 0.59 0.73 0.7
Net Profit 0.67 0.72 1.09 1.59 1.52
Adjusted EPS (Rs.) 0.94 1.02 1.38 1.8 1.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 7.08 7.08 7.92 8.81 9.66
Total Reserves 21.71 22.16 25.57 27.66 29.58
Borrowings 0.18 0 0 0 0
Other N/C liabilities 0.81 0.85 0.95 0.94 1.04
Current liabilities 13.86 11.33 12.52 11.87 13.88
Total Liabilities 43.64 41.41 46.96 49.28 54.17
Assets
Net Block 17.04 16.6 16.17 16 16.62
Capital WIP 0 0 0 0.48 0.42
Intangible WIP 0 0 0 0 0
Investments 1.13 0.82 0.24 9.11 9.66
Loans & Advances 5.1 1.32 0 0 0
Other N/C Assets 0.28 0.25 0 0.05 1.94
Current Assets 20.08 22.42 30.54 23.65 25.54
Total Assets 43.64 41.41 46.96 49.28 54.17
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1.02 0.92 1.68 2.32 2.22
Adjustment 1.69 0.96 0.62 0.63 0.48
Changes in Assets & Liabilities 1.35 4.47 5.75 -1.13 -1.78
Tax Paid -0.31 -0.14 -0.46 -0.88 -0.7
Operating Cash Flow 3.74 6.2 7.59 0.95 0.22
Investing Cash Flow -0.1 -0.37 -5.58 -5.47 0.53
Financing Cash Flow -4.26 -5.36 1.3 0.93 0.58
Net Cash Flow -0.62 0.48 3.31 -3.59 1.33

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 42.90 42.90 42.90 42.90 42.90
akshath finvest and prope... 5.12 5.12 5.12 5.12 5.12
geeta u sandu 0.88 0.88 0.88 0.88 0.88
jayshree bhaskar sandu 7.63 7.63 7.63 7.63 7.63
minal shashank sandu 0.63 0.63 0.63 0.63 0.63
shashank bhaskar sandu 14.17 14.17 14.17 14.17 14.17
shubhada prabhakar sandu 0.10 0.10 0.10 0.10 0.10
umesh bhaskar sandu 14.37 14.37 14.37 14.37 14.37
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 57.10 57.10 57.10 57.10 57.10
hitesh kuvelkar 1.26 1.26 1.26 1.26 1.26
llp 0.02 0.05 0.32 0.34 0.35
neelamber leasing and fin... 4.71 4.71 4.71 4.71 4.71
noumura realty and constr... 2.27 2.27 2.27 2.27 2.27
phybrichem engineers priv... 1.61 1.61 1.61 1.61 1.61
sanbro marketing services... 2.59 2.59 2.59 2.59 2.59
sanmark realty and financ... 5.63 5.63 5.63 5.63 5.63
tanvi jignesh mehta 2.63 2.60 2.57 2.41 2.54
trans scan securities pri... - - 1.10 1.04 -
yogish shetty 1.10 1.10 1.10 1.07 -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Sandu Pharmaceuticals informs about closure of trading window23 Sep 2024, 12:16PM Sandu Pharmaceuticals informs about stop transfer request 21 Sep 2024, 10:28AM Sandu Pharmaceuticals informs about stop transfer request 21 Aug 2024, 3:18PM Sandu Pharmaceutical - Quaterly Results12 Aug 2024, 7:36PM Sandu Pharmaceutical - Quaterly Results12 Aug 2024, 7:36PM Sandu Pharmaceuticals informs about details of loss of certificate8 Aug 2024, 2:29PM Sandu Pharmaceuticals informs about board meeting3 Aug 2024, 2:28PM Sandu Pharmaceuticals informs about stop transfer request 20 Jun 2024, 1:01PM Sandu Pharmaceutical - Quaterly Results5 Jun 2024, 7:22PM Sandu Pharmaceutical - Quaterly Results5 Jun 2024, 7:22PM Sandu Pharmaceuticals informs about loss of share certificate 14 May 2024, 2:12PM Sandu pharmaceuticals informs about details of loss of certificate 4 May 2024, 11:24AM Sandu Pharmaceuticals informs about stop transfer receipt 30 Apr 2024, 12:44PM Sandu Pharmaceuticals informs about details of loss of certificate 16 Apr 2024, 4:58PM Sandu Pharmaceuticals informs about compliance certificate11 Apr 2024, 1:36PM Sandu Pharmaceuticals informs about stop transfer request 30 Mar 2024, 11:10AM Sandu Pharmaceuticals informs about details of loss of certificate 20 Mar 2024, 1:01PM Sandu Pharmaceuticals informs about details of loss of certificate8 Mar 2024, 12:24PM Sandu Pharmaceutical - Quaterly Results14 Feb 2024, 9:04PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate20 Jan 2024, 12:30PM Sandu Pharmaceuticals informs about resignation of CFO22 Nov 2023, 5:12PM Sandu Pharmaceuticals informs about details of loss of certificate 18 Nov 2023, 10:59AM Sandu Pharmaceuticals informs about stop transfer request 21 Oct 2023, 11:06AM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 25 Sep 2023, 10:50AM Sandu Pharmaceuticals informs about issuance of duplicate shares certificate 6 Sep 2023, 12:28PM Sandu Pharmaceuticals informs about stop transfer intimation 11 Aug 2023, 11:55AM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 29 Jul 2023, 10:17AM Sandu Pharmaceuticals informs about loss of share certificates21 Jul 2023, 12:15PM Sandu Pharmaceuticals informs about loss of share certificate 15 Jul 2023, 10:29AM Sandu Pharmaceuticals informs about loss of share certificate1 Jul 2023, 12:27PM Sandu Pharmaceuticals informs about loss of share certificate15 Jun 2023, 2:30PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate9 May 2023, 12:29PM Sandu Pharmaceuticals informs about closure of trading window 23 Mar 2023, 12:23PM Sandu Pharmaceuticals informs about details of loss of certificate18 Mar 2023, 3:45PM Sandu Pharmaceuticals informs about stop transfer request 14 Mar 2023, 12:42PM Sandu Pharmaceuticals informs about disclosure 25 Feb 2023, 2:25PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate20 Feb 2023, 3:18PM Sandu Pharmaceuticals informs about newspaper cutting16 Feb 2023, 4:45PM Sandu Pharmaceuticals informs about stop transfer request6 Feb 2023, 10:36AM Sandu Pharmaceuticals informs about loss of share certificate 27 Jan 2023, 11:46AM Sandu Pharmaceuticals informs about loss of share certificates17 Dec 2022, 4:45PM Sandu Pharmaceuticals inks MoU with Bach Ma Van Xuan Pharmaceuticals12 Dec 2022, 9:47AM Sandu Pharmaceuticals informs about loss of share certificate1 Dec 2022, 12:29PM Sandu Pharmaceuticals informs about details of loss of certificate 8 Nov 2022, 3:21PM Sandu Pharmaceuticals informs about stop transfer request 21 Oct 2022, 12:37PM Sandu Pharmaceuticals informs about stop transfer request 17 Oct 2022, 10:29AM Sandu Pharmaceuticals informs about proceedings of AGM 1 Oct 2022, 12:21PM Sandu Pharmaceuticals informs about disclosure26 Sep 2022, 12:45PM Sandu Pharmaceuticals informs about closure of trading window24 Sep 2022, 11:05AM Sandu Pharmaceuticals board to recommend dividend30 Jul 2022, 11:44AM

Sandu Pharmaceutical Stock Price Analysis and Quick Research Report. Is Sandu Pharmaceutical an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sandu Pharmaceutical and its performance over the period of time. Sandu Pharmaceutical stock price today is Rs 55.01.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sandu Pharmaceutical cash from the operating activity was Rs 0.2212 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sandu Pharmaceutical has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sandu Pharmaceutical , the EPS growth was -12.5512806297816 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sandu Pharmaceutical has OPM of 3.80923962111124 % which is a bad sign for profitability.
     
  • ROE: Sandu Pharmaceutical have a poor ROE of 5.30446087790411 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sandu Pharmaceutical is Rs 55.01. One can use valuation calculators of ticker to know if Sandu Pharmaceutical share price is undervalued or overvalued.
Last Updated on:
Brief about Sandu Pharmaceutical
X